Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31698360 | 0.81 | ABL1 (0.39) | HCAR1 | |
| SCHEMBL24534061 | 0.80 | GLA (0.35) | DPP4FLT1KDRPDE3BPDE3A | |
| SCHEMBL20698154 | 0.77 | PRPS1 (0.41) | DPP4C1SGDA | |
| SCHEMBL25922278 | 0.77 | HCAR1 (0.34) | HCAR1 | |
| SCHEMBL31698506 | 0.77 | MEN1 (0.45) | HCAR1 | |
| SCHEMBL31362139 | 0.75 | NQO2 (0.37) | HCAR1HTTDPP4GDA | |
| SCHEMBL26626466 | 0.75 | NQO2 (0.37) | HCAR1HTTDPP4GDA | |
| SCHEMBL31698452 | 0.75 | AR (0.41) | HCAR1 | |
| SCHEMBL31349605 | 0.75 | HCAR1 (0.33) | HCAR1 | |
| SCHEMBL31698308 | 0.74 | HCAR1 (0.34) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | HCAR1 2434/4885HTT 1460/4885DPP4 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.